Phase 2 Uveitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older, of any gender
- People who have been diagnosed with non-infectious uveitis affecting the middle, back, or whole eye (not just the front), with a diagnosis history of more than one year
- People who have active disease at the start of the trial while taking a stable dose of oral prednisone for at least two weeks
- People whose eye condition has previously responded adequately to oral corticosteroid (steroid) treatment, as determined by the trial doctor
- People who do not plan to become pregnant and are willing to use highly effective contraception throughout the study and for 24 weeks after the last dose of the study drug
- People who are able to understand the study procedures, agree to take part voluntarily, sign a consent form, and follow all study requirements through to completion
Who may not be able to join:
- People whose uveitis affects only the front part of the eye (anterior uveitis only)
- People who have certain serious eye conditions, including wet age-related macular degeneration, advanced diabetic retinopathy, or significant diabetes-related swelling in the central part of the retina
- People who have other inflammatory diseases in the body that require ongoing treatment with oral steroids or certain immune-suppressing medications
- People with a confirmed active tuberculosis (TB) infection, including cases identified on imaging; people with latent or high-risk TB may still be considered, provided the trial doctor does not consider them unsuitable and they are willing to continue TB treatment as required (confirm with trial site)
- People with serious uncontrolled health conditions, including very high blood pressure (at or above 200/105 mmHg), advanced heart failure, or poorly controlled diabetes with high blood sugar levels; the trial doctor will make the final determination on eligibility
- People who have received anti-TNF therapy or certain other biological treatments that could affect uveitis within 12 weeks before the start of the trial (injections into the eye for a different purpose are excluded from this rule)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86 18301941524
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The effectiveness of GenSci048 administered by subcutaneous injection
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.